News & Updates
Showing Ophthalmology articles
Showing
Show Multimedia Only

SGLT2 inhibitors potentially protective against dry eye disease
29 Sep 2022
byJairia Dela Cruz
Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.
29 Sep 2022

Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.
03 Sep 2022






